{
  "id": "engraftment",
  "title": "Engraftment",
  "lang": "en",
  "source_lang": "en",
  "summary": "Engraftment is the establishment of transplanted cells or tissue in a recipient, most commonly assessed by blood-cell recovery after hematopoietic stem cell transplantation.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Graft establishment"
  ],
  "generated_at": "2026-11-04",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/engraftment/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/engraftment/",
      "json": "https://aiwiki.page/zh/engraftment.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Engraftment is the process by which transplanted cells or tissue survive and become established in a recipient, contributing to biological function. The term is used especially in hematopoietic stem cell transplantation, where transplanted blood-forming cells settle in the bone marrow and begin producing blood cells. Engraftment is a process rather than the act of administering a transplant, and its assessment depends on the type of graft."
    },
    {
      "heading": "Biological basis",
      "text": "In blood-forming cell transplantation, infused hematopoietic stem cells and their progenitors travel through the circulation to supportive environments in the marrow. This initial movement and localization is called homing. Interactions with marrow support cells, adhesion molecules, and chemical signals help the transplanted cells remain in these environments, survive, and produce mature blood cells.\n\nHoming is necessary for engraftment but is not equivalent to it. Cells may reach the marrow without establishing sustained blood production. Early blood-cell recovery can arise from relatively short-lived progenitor cells, whereas durable blood formation depends on the persistence and self-renewal of longer-lived stem cells.\n\nPreparative treatment, commonly called conditioning, may include chemotherapy, radiation therapy, or both. Depending on the transplantation procedure, conditioning suppresses the recipient’s immune response, treats the underlying disease, and alters the marrow environment to support graft establishment. The recipient’s immune system can otherwise recognize donor cells as foreign and impede their persistence."
    },
    {
      "heading": "Autologous and allogeneic engraftment",
      "text": "In autologous transplantation, the recipient receives previously collected cells from their own body. Engraftment restores blood production after intensive treatment. Donor–recipient immune incompatibility is not an issue, although graft quality, treatment effects, infection, and other factors can still delay recovery.\n\nIn allogeneic transplantation, cells come from another person. Engraftment establishes donor-derived blood formation and, over time, contributes to rebuilding immune function. Donor compatibility, including matching of human leukocyte antigens, affects transplantation outcomes. Successful transplantation is also possible with partially matched donors, including through haploidentical transplantation, using appropriate transplantation protocols.\n\nBlood-forming grafts may be collected from peripheral blood, bone marrow, or umbilical cord blood. These sources differ in cell composition and typical recovery patterns. Peripheral blood grafts generally produce faster blood-count recovery than marrow grafts, while cord blood grafts commonly take longer."
    },
    {
      "heading": "Assessment and clinical milestones",
      "text": "Engraftment after blood-forming cell transplantation is usually assessed through repeated complete blood counts. Different blood-cell types recover at different rates, so engraftment is not necessarily a single event.\n\nCommon operational definitions include:\n\n- Neutrophil engraftment: the first of three consecutive days with an absolute neutrophil count of at least \\(0.5 \\times 10^9/L\\).\n- Platelet engraftment: recovery to a platelet count of at least \\(20 \\times 10^9/L\\), sustained without platelet transfusion support for a defined interval, commonly seven days.\n\nDefinitions vary among registries, studies, and transplantation programs. Some use additional platelet thresholds or different confirmation periods. Reported engraftment times therefore depend partly on the criteria used.\n\nNeutrophil recovery often occurs within the first few weeks after transplantation, but timing varies substantially with graft source, cell dose, conditioning, and complications. Platelet recovery may follow a different course. Recovery of lymphocyte populations and effective immune responses generally takes considerably longer than initial neutrophil recovery.\n\nIn allogeneic transplantation, chimerism testing measures the relative contributions of donor and recipient cells, usually using genetic differences between them. Testing can examine whole blood or selected cell populations. Mixed chimerism means that both donor-derived and recipient-derived blood-forming cells are detectable. Its significance depends on the underlying disease, treatment protocol, cell population tested, and changes over time; it does not invariably indicate graft failure."
    },
    {
      "heading": "Delayed engraftment and graft failure",
      "text": "Delayed engraftment describes slower-than-expected recovery. Primary graft failure means that the graft does not establish adequate blood production within the relevant clinical definition. Secondary graft failure refers to loss of graft function after initial recovery. Exact definitions and time limits differ by transplantation setting and graft source.\n\nPotential contributors include an insufficient number of functional transplanted cells, immune-mediated graft rejection, infection, medication toxicity, and damage to the marrow environment. Donor-specific antibodies can also interfere with engraftment in some allogeneic settings.\n\nPoor graft function is a related but distinct condition in which blood-cell production remains inadequate despite established donor chimerism. It should not automatically be equated with rejection. Persistent low blood counts may also result from recurrence of the original disease or other complications.\n\nBefore blood production recovers, neutropenia increases susceptibility to infection, while low platelet and red-cell counts can create a need for transfusion support. Achieving engraftment reduces some of these early vulnerabilities but does not establish complete immune recovery."
    },
    {
      "heading": "Engraftment syndrome and other distinctions",
      "text": "Engraftment syndrome is an inflammatory complication occurring around blood-cell recovery. Features can include otherwise unexplained fever, skin rash, fluid retention, and respiratory impairment. Diagnostic criteria vary, and these findings can overlap with infection, medication reactions, and other transplantation complications.\n\nEngraftment is distinct from graft-versus-host disease, in which donor immune cells attack recipient tissues. It is also distinct from the graft-versus-leukemia effect, in which donor immune cells act against residual leukemia. Successful donor engraftment can coexist with either phenomenon.\n\nEngraftment does not by itself demonstrate cure of the underlying disease, freedom from later graft loss, or complete restoration of immune function."
    },
    {
      "heading": "Use beyond blood-forming cell transplantation",
      "text": "The term also applies to transplanted tissues and other cell products. In skin grafting, establishment involves adherence, survival, and development of a blood supply. In transplantation of pancreatic islets, engraftment concerns the survival and functional establishment of the transplanted cells.\n\nIn solid-organ transplantation, successful graft establishment likewise requires adequate perfusion and functioning tissue, although organ-specific measures are generally more informative than the term “engraftment” alone. Measures of engraftment are therefore not interchangeable across transplant types."
    }
  ],
  "links": [
    "hematopoietic-stem-cell-transplantation",
    "bone-marrow",
    "chemotherapy",
    "radiation-therapy",
    "immune-system",
    "human-leukocyte-antigen",
    "haploidentical-transplantation",
    "complete-blood-count",
    "transplant-rejection",
    "neutropenia",
    "blood-transfusion",
    "fever",
    "graft-versus-host-disease",
    "graft-versus-leukemia-effect",
    "pancreatic-islets",
    "organ-transplantation"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}